Anavex Life Sciences マネジメント
マネジメント 基準チェック /44
Anavex Life Sciencesの CEO はChris Misslingで、 Jul2013年に任命され、 の在任期間は 11.33年です。 の年間総報酬は$ 3.89Mで、 18%給与と82%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.47%を直接所有しており、その価値は$ 11.30M 。経営陣と取締役会の平均在任期間はそれぞれ2.8年と10.5年です。
主要情報
Chris Missling
最高経営責任者
US$3.9m
報酬総額
| CEO給与比率 | 18.0% |
| CEO在任期間 | 11.3yrs |
| CEOの所有権 | 1.5% |
| 経営陣の平均在職期間 | 2.8yrs |
| 取締役会の平均在任期間 | 10.5yrs |
経営陣の近況
Recent updates
Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease
Nov 11Anavex: Understanding Their Latest Alzheimer's Data News With Caution
Nov 05Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)
Oct 08Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising
Jul 29Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth
Jul 17
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Apr 01Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Sep 19We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
May 10Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth
Jan 16We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Oct 01Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia
Sep 19Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease
Sep 07Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01
Aug 09We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Jun 17Anavex: Increasing Shareholder Value Against All Odds
May 31Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease
Mar 23We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn
Mar 03Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease
Feb 09Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity
Feb 02Anavex: 2022 Has Major, Pivotal Catalysts
Jan 17Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Nov 16Alzheimer's - Cassava, Cortexyme Or Anavex: Who Will Come On Top?
Nov 05Anavex Life Sciences: Still Room To Run
Aug 29Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Jul 30Anavex: A Catalyst-Rich Year
Jul 05Virpax Pharmaceuticals, Anavex Life Sciences leads healthcare gainers; Aptevo Therapeutics, Intec Pharma among major losers
Jun 21Anavex Life outlines mechanism of ANAVEX2-73 and ANAVEX3-71 in treatment of Alzheimer's Disease
Jun 14Anavex Life's late-stage ANAVEX2-73 study in Alzheimer’s exceeds target enrollment
Jun 08Anavex, Cyclo Therapeutics, And Green Valley: Stalling The Progression Of Alzheimer's Disease
Apr 28Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Apr 16CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$42m |
| Mar 31 2024 | n/a | n/a | -US$41m |
| Dec 31 2023 | n/a | n/a | -US$43m |
| Sep 30 2023 | US$4m | US$700k | -US$48m |
| Jun 30 2023 | n/a | n/a | -US$52m |
| Mar 31 2023 | n/a | n/a | -US$53m |
| Dec 31 2022 | n/a | n/a | -US$50m |
| Sep 30 2022 | US$7m | US$586k | -US$48m |
| Jun 30 2022 | n/a | n/a | -US$45m |
| Mar 31 2022 | n/a | n/a | -US$43m |
| Dec 31 2021 | n/a | n/a | -US$41m |
| Sep 30 2021 | US$9m | US$550k | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$32m |
| Mar 31 2021 | n/a | n/a | -US$28m |
| Dec 31 2020 | n/a | n/a | -US$28m |
| Sep 30 2020 | US$2m | US$550k | -US$26m |
| Jun 30 2020 | n/a | n/a | -US$26m |
| Mar 31 2020 | n/a | n/a | -US$26m |
| Dec 31 2019 | n/a | n/a | -US$26m |
| Sep 30 2019 | US$3m | US$513k | -US$26m |
| Jun 30 2019 | n/a | n/a | -US$26m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | n/a | n/a | -US$20m |
| Sep 30 2018 | US$3m | US$500k | -US$17m |
報酬と市場: Chrisの 総報酬 ($USD 3.89M ) は、 US市場 ($USD 3.15M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Chrisの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Chris Missling (58 yo)
11.3yrs
在職期間
US$3,894,453
報酬
Dr. Christopher U. Missling, also known as the Chris, MS, Ph D., MBA, has been the Chief Executive Officer and President at Anavex Life Sciences Corp. since July 05, 2013 and also serves as its Director an...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 11.3yrs | US$3.89m | 1.47% $ 11.3m | |
| Principal Financial Officer & Treasurer | 9.1yrs | US$501.06k | 0.027% $ 207.5k | |
| Chief Scientific Officer | 2.8yrs | データなし | データなし | |
| VP of Corporate | no data | データなし | データなし | |
| Senior Vice President of Nonclinical Development | 3.5yrs | データなし | データなし | |
| Chief Medical Officer | 2.8yrs | データなし | データなし | |
| Head of Biostatistics | 1.7yrs | データなし | データなし | |
| Senior Vice President of Regulatory Affairs | less than a year | データなし | データなし | |
| Senior Vice President of Clinical Development | less than a year | データなし | データなし | |
| Senior VP & Head of Research and Development | less than a year | データなし | データなし |
2.8yrs
平均在職期間
経験豊富な経営陣: AVXLの経営陣は 経験豊富 であると考えられます ( 2.8年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 11.3yrs | US$3.89m | 1.47% $ 11.3m | |
| Independent Chairman | 3.5yrs | US$349.54k | データなし | |
| Member of the Scientific Advisory Board | 9.7yrs | データなし | データなし | |
| Member of the Scientific Advisory Board | 13.8yrs | データなし | データなし | |
| Member of the Scientific Advisory Board | 10.9yrs | データなし | データなし | |
| Member of the Scientific Advisory Board | 11yrs | データなし | データなし | |
| Member of the Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 11.8yrs | US$341.54k | 1.54% $ 11.8m | |
| Member of the Scientific Advisory Board | 10.5yrs | データなし | データなし | |
| Member of the Scientific Advisory Board | 9.7yrs | データなし | データなし | |
| Independent Director | 9.4yrs | US$341.54k | 0.0059% $ 45.2k | |
| Lead Independent Director | 6.7yrs | US$357.54k | データなし |
10.5yrs
平均在職期間
58yo
平均年齢
経験豊富なボード: AVXLの 取締役会 は経験豊富で 経験豊富 です ( 10.5年の平均在任期間)。